NCT07283718

Brief Summary

This is a real-world multicentre study to investigate the metastatic pattern of axillary lymph node and its association with breast cancer prognosis.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
2,467

participants targeted

Target at P75+ for all trials

Timeline
5mo left

Started Sep 2025

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress61%
Sep 2025Sep 2026

Study Start

First participant enrolled

September 28, 2025

Completed
13 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 11, 2025

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

December 4, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 16, 2025

Completed
10 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 28, 2026

Expected
Last Updated

December 16, 2025

Status Verified

December 1, 2025

Enrollment Period

13 days

First QC Date

December 4, 2025

Last Update Submit

December 4, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Disease free survival

    Disease-free survival time is defined as the time from the date of axillary lymph node dissection until the date of the first occurrence of local/regional relapse, distant recurrence, contralateral breast cancer, second malignancy and death from any cause.

    From the date of ALND until time of event up to 3 years

Secondary Outcomes (2)

  • Recurrence-free survival

    From the date of ALND until time of event up to 3 years

  • Overall survival

    From the date of ALND until time of event up to 3 years

Study Arms (1)

ALND

breast cancer patients receiving axillary lymph mode dissection

Procedure: ALND

Interventions

ALNDPROCEDURE

axillary lymph node dissection

ALND

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients were pathologically diagnosed primary invasive breast cancer from October 2013 to December 2023. They had axillary lymph node dissection.

You may qualify if:

  • Aged 18 years or older
  • Pathologically confirmed invasive primary breast cancer

You may not qualify if:

  • De novo stage IV breast cancer

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Renji Hospital, School of Medicine, Shanghai Jiaotong University

Shanghai, 200127, China

Location

Study Officials

  • Wenjin Yin, M.D.

    Renji Hospital, School of Medicine, Shanghai Jiao Tong University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Deputy Chief of Breast Surgery Department

Study Record Dates

First Submitted

December 4, 2025

First Posted

December 16, 2025

Study Start

September 28, 2025

Primary Completion

October 11, 2025

Study Completion (Estimated)

September 28, 2026

Last Updated

December 16, 2025

Record last verified: 2025-12

Locations